ID	Common Topics	L1D	Topics	Examples
L2D134 (1.2)	T47 (21%): mastectomy (17%), invasive (15%), dcis (14%), contralateral (12%) T362 (6%): breast_cancer (53%), breast (27%) T60 (4%): er (18%), er+ (15%), estrogen_receptor (13%), premenopausal (12%), er_pr (10%) T386 (4%): women (100%) T15 (3%): age (43%) T341 (3%): diagnosis (44%), diagnosed (35%) T97 (3%): family_history (52%), brca (35%) T212 (2%): reviewed (23%), records (20%), presenting (12%), medical_records (12%) T80 (2%): screening (100%) T143 (2%): tumor_size (34%), node_negative (25%), nodal_status (18%)	L1D431 (1.5)	T47 (28%): stopped_hrt (3%), dcis (2%), taking_hrt (2%), contralateral (2%), lumpectomy (2%) T80 (4%): screening (7%), polyps (6%), transvaginal (5%), annual (4%), mammogram (4%) T140 (4%): endometrial (13%), endometrium (10%), endometrial_cancer (8%) T46 (3%): ultrasound (6%), masses (4%), bilateral (4%), cysts (4%), atrophic (4%) T362 (3%): breast_cancer (53%), breast (38%) T256 (3%): interval (30%), after (18%) T152 (2%): recurred_locally (12%), local_recurrence (11%), distant_recurrences (10%), local_recurrences (9%) T57 (2%): tamoxifen (14%), endometrial_thickness (8%) T386 (2%): women (33%), hrt (30%), prospective_single-arm (22%)	Breast MRI in elderly patients with breast cancer: Does breast density matter? Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening. Endometrial assessment in postmenopausal women with high risk factors of endometrial cancer by transvaginal ultrasound. The Effect of Adjuvant Tamoxifen (T) on The Endometrium in Women with Breast Cancer: A Prospective Study (Meeting abstract). Influence of loco-regional radiation therapy on subsequent cancer risk among BC pts with p53 germline mutations.
		L1D449 (1.4)	T47 (16%): mastectomy (5%), dcis (4%), ductal_carcinoma (3%), invasive_breast (3%), invasive (3%) T73 (9%): race (6%), seer_database (4%), white (4%), surveillance_epidemiology (4%), seer (3%) T33 (4%): white_women (4%), black_women (3%), less_likely (3%), disparity (3%), population-based (3%) T15 (4%): age (30%), younger (19%), older (18%) T341 (3%): diagnosed (29%), diagnosis (28%) T170 (3%): higher (23%), compared (17%), than (13%) T135 (3%): more_likely (18%), trends (10%) T362 (3%): breast_cancer (57%), breast (29%) T212 (3%): presentation (22%), reviewed (11%) T72 (2%): hospital (13%), national (8%) T143 (2%): tumor_size (24%)	Rate of breast conserving surgery versus mastectomy in Hispanic/Latina women with breast cancer in El Paso, TX. Metastatic breast cancer in males: Impact of primary tumor resection. Clinical-pathologic characteristics of true interval and screen-detected breast cancer among participants in a Canadian breast screening program: A nested case-control study. Comparison of primary and secondary breast cancer in adolescents and young adults (AYA). Benefits of screening mammography in women aged 40-49 with invasive breast cancer (Meeting abstract).
		L1D711 (1.4)	T47 (23%): mammography (4%), dcis (4%), mastectomy (3%), invasive (3%), contralateral_breast (3%) T97 (14%): family_history (7%), carriers (6%), brca1 (6%), prophylactic_mastectomy (4%), brca_mutation (4%) T80 (7%): mammogram (7%), surveillance (7%), mammograms (6%), chemoprevention (5%), screening (5%) T362 (4%): breast (46%), breast_cancer (45%) T246 (4%): risk (41%), increased_risk (24%)	Breast Conservation Therapy for Familial Breast Cancer. A retrospective review of wide excision alone for ductal carcinoma in situ (DCIS) of the breast. MRI characteristics of BRCA-associated breast cancers. The reliability of ductal lavage in women at high risk for breast cancer Breast tumor location in BRCA mutation carriers and implications for prevention.
		L1D758 (1.5)	T222 (10%): recommendations (11%), recommendation (10%) T127 (8%): oncologists (9%), physicians (6%) T60 (7%): score_rs (10%), intermediate_rs (8%), onco_type (7%), oncotype_dx (6%) T143 (4%): node-negative (11%), node_negative (10%), lymphovascular_invasion (6%) T287 (4%): rs (41%) T215 (4%): treatment_decisions (15%), decisions (8%) T33 (3%): receipt (7%), underuse (5%), receptor-positive_her2-negative (4%), georgia (4%), less_likely (4%) T345 (2%): adjuvant (50%), adjuvant_chemotherapy (35%) T260 (2%): use (36%) T78 (2%): survey (10%), physicians’ (5%), preferences (5%), cognitive_interviews (5%) T343 (2%): care (36%) T150 (2%): comorbidities (20%), comorbidity (19%) T58 (2%): claims (7%), reimbursed (6%), utilization (5%), community_oncology (5%), using_generalized (4%)	Adherence to clinical practice guidelines for adjuvant therapy of breast cancer. Population-based evaluation of 21-gene assay in treatment decision making for early breast cancer in Ontario. Utilization of the 21-gene assay for breast cancer treatment decision-making in Alberta. Effect of a genomic classifier on adjuvant treatment decision-making among patients with high-risk pathology at radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study. Pattern of presentation and treatment of early primary breast cancer in the elderly.
		L1D772 (1.5)	T97 (39%): brca1 (6%), brca2 (4%), carriers (4%), brca (4%), brca1_mutations (3%) T6 (5%): ovarian_cancer (31%) T105 (5%): reproductive (5%), oral_contraceptive (5%), breastfeeding (4%), pregnancy (4%), young_women (4%) T191 (3%): mutations (35%), mutation (26%)	Breast Cancer in Women Previously Exposed to Fertility Drug Therapy: Comparision with Pregnancy Associated Breast Cancer and a Large Group of Controls. Effect of reproductive factors and lifestyle on the onset of breast cancer in female BRCA 1 and 2 mutation carriers. Family history (FH) of women with breast cancer (BC) and acute myelogenous leukemia (AML). Survival in advanced-stage ovarian cancer patients with non-Ashkenazi Jewish BRCA mutations. Retrospective analysis: Patients with ovarian cancer at National Cancer Institute of Mexico.
L2D139 (1.4)	T97 (18%): family_history (19%), genetic_testing (18%) T80 (10%): screening (23%), individuals (14%) T78 (8%): education (14%), survey (9%), perception (9%), perceived (8%), awareness (7%) T96 (6%): participants (18%), counseling (12%) T33 (3%): insurance (23%) T127 (3%): services (13%), health_care (11%), referral (11%), barriers (7%), practices (7%) T216 (2%): their (30%), family (24%), about (17%) T246 (2%): risk (64%)	L1D439 (1.7)	T78 (22%): education (4%), disclosure (3%), perceived (2%), perception (2%) T97 (18%): genetic_testing (8%), genetic_counseling (5%), family_history (5%), brca1 (4%) T96 (10%): knowledge (9%), counseling (8%), participants (8%), personal (5%) T67 (6%): questionnaire (8%), anxiety (5%), psychological (5%), distress (5%), questionnaires (4%)	Parental disclosure of genetic test results to young adults, adolescents and children. Knowledge and perceptions of breast cancer risk in adolescent girls at high risk and population risk for breast cancer. The association of risk perception with distress and health behaviors among individuals with a family history of cancer Hereditary nonpolyposis colorectal cancer (HNPCC) family members' perceptions of the duty to disclose mutation information Hereditary breast-ovarian cancer knowledge and interest in genetic testing among African American women.
		L1D553 (1.4)	T80 (15%): screening (11%) T33 (9%): population-based (3%), age-standardized (2%), disparities (2%), south (2%), race_ethnicity (2%) T73 (8%): surveillance_epidemiology (7%), seer (7%), race (4%) T325 (4%): period (16%), over (12%), increasing (11%), end (10%) T109 (3%): mortality (27%) T273 (3%): population (35%) T15 (3%): age (36%) T341 (2%): diagnosed (28%), registry (23%), diagnosis (20%) T135 (2%): trends (32%) T163 (2%): increase (31%), decrease (17%) T72 (2%): national (26%), united_states (14%)	Higher incidence and mortality rates of cervical cancer in African-American women in Louisiana. Predictors of compliance in colposcopy clinic follow-up among the uninsured. Estimating the risk of individuals of developing cutaneous melanoma (Meeting abstract). Time-related changes in yield and harms of screening breast MRI. Disparities in age-related incidence of colon and rectal cancer in the United States, 1975-2010.
		L1D709 (1.5)	T97 (40%): family_history (4%), genetic_testing (4%), families (3%), genetic_counseling (3%), brca1 (2%) T80 (5%): screening (15%), individuals (10%) T96 (3%): family_members (10%), counseling (10%), clinic (8%), personal (8%), participants (6%) T6 (2%): ovarian_cancer (50%)	Optimal selection of individuals for BRCA1 and BRCA2 gene testing. Preliminary analysis of genetic counselling activity at Regina Elena Cancer Institute of Rome - Italy. Identification of Von Hippel-Lindau Disease in Patients with Cerebellar Hemangioblastomas. (Meeting abstract). Evaluating a novel oncologist-led BRCA1/2 mutation ( BRCA m) testing counseling model for patients with ovarian cancer: Interim results from the ENGAGE study. Incidence and Therapeutic Options of BRCA1/2 Carriers: High Risk Cohort Participating in Phase II Chemoprevention Trial.
L2D141 (1.3)	T38 (16%): bmi (19%), body_mass (16%), obesity (15%), index_bmi (14%), obese (11%) T89 (6%): smoking (51%) T73 (4%): race (33%), white (18%) T76 (4%): after_adjusting (16%), worse (16%), variables (10%), after_adjustment (8%) T135 (4%): more_likely (16%), adjusted (14%) T170 (3%): compared (31%), higher (29%) T244 (2%): multivariate_analysis (19%), prognostic_factor (14%), prognostic (14%), an_independent (13%), prognostic_factors (10%) T274 (2%): multivariate_cox (17%), cox_regression (14%), cox_proportional (14%) T138 (2%): subtypes (50%), subtype (50%) T106 (2%): differences (30%), statistically_significant (17%) T15 (2%): age (61%) T341 (2%): diagnosed (38%), diagnosis (36%) T337 (2%): association (44%), association_between (26%)	L1D441 (1.5)	T89 (37%): smoking (10%), smokers (5%) T275 (4%): lung_cancer (42%) T124 (3%): head (10%), spt (8%), neck (5%) T309 (3%): adenocarcinoma (30%), squamous_cell (19%) T306 (2%): female (27%), gender (27%), male (14%) T246 (2%): risk (32%), risk_factors (22%), increased_risk (18%)	Lung cancer diagnosis is being made with increasing frequency in former cigarette smokers (Meeting abstract). Tamoxifen does not reduce the risk of lung cancer in women Alcohol consumption and prognosis in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance). Head and neck squamous cell carcinoma (HNSCC), diabetes mellitus (DM), and metformin. Association between smoking history and disease-free and overall survival in resected gastric cancer.
		L1D732 (1.5)	T73 (12%): race (7%), african_american (5%), caucasian (4%) T60 (11%): er_pr (13%), er (10%), estrogen_receptor (9%) T138 (9%): triple_negative (13%), subtype (10%), subtypes (10%) T160 (5%): her2 (22%) T33 (4%): race_ethnicity (4%), socioeconomic_status (4%), less_likely (4%), white_women (4%), marital_status (3%) T362 (3%): breast_cancer (60%) T15 (3%): age (40%), younger (21%) T170 (2%): higher (25%), compared (19%), distribution (19%) T135 (2%): more_likely (22%)	Association of age with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry. Breast cancer survival: Is the Asian population homogenous? Higher volumetric breast density to predict risk for aggressive breast cancer subtype in postmenopausal Korean women. Histologic subtypes of ductal intraepithelial neoplasia (DIN) of the breast: Characteristic associations and biology. Are there disparities in adjuvant treatment of HER2 positive breast cancer patients by age, race/ethnicity, and socioeconomic status?
		L1D755 (1.5)	T38 (41%): bmi (8%), obesity (7%), body_mass (7%), index_bmi (6%), obese (4%) T60 (3%): menopausal_status (18%) T76 (3%): after_adjusting (11%), worse (9%) T244 (3%): multivariate_analysis (13%), prognostic (11%), prognostic_factors (10%), an_independent (8%)	A single-center experience with CELLSEARCH system circulating tumor cell test on patients with metastatic breast cancer. Prognostic score for Luminal A-like breast cancer patients. Relationship of glucose disorders and body mass index with pathologic complete response to neoadjuvant chemotherapy in breast cancer. Relating tissue selenium to anthropometric and receptor status in Nigerian patients with breast cancer. Obesity and survival in the neoadjuvant breast cancer setting: Role of tumor subtype and race.
L2D159 (1.3)	T109 (13%): general_population (32%), mortality (18%) T80 (8%): screening (20%), individuals (12%) T195 (4%): survivors (24%), children (20%), pediatric (17%), retinoblastoma (14%), adult (13%) T341 (4%): diagnosed (37%), diagnosis (24%) T355 (3%): incidence (61%) T246 (3%): risk (25%), risk_factors (21%), increased_risk (18%) T33 (3%): population-based (48%), registries (40%) T43 (3%): cases (40%), malignancy (29%) T15 (3%): age (38%) T72 (3%): national (25%) T115 (3%): newly_diagnosed (100%) T140 (3%): cervical_cancer (44%), cervix (26%)	L1D479 (1.6)	T109 (25%): standardized_incidence (10%), sir (6%) T195 (7%): survivors (20%), childhood (14%) T246 (6%): risk (23%), increased_risk (23%), developing (17%) T26 (3%): leukemia (17%), acute_myeloid (9%) T73 (3%): surveillance_epidemiology (24%), seer (17%), seer_database (13%) T157 (3%): soft_tissue (13%), sarcomas (12%), sarcoma (10%) T341 (3%): diagnosis (36%), diagnosed (30%) T99 (2%): non-hodgkin_lymphoma (8%), lymphoma (6%), hodgkin_lymphoma (6%), nhl (5%), hodgkin_disease (5%)	Doxorubicin is a significant risk factor for second malignant tumors (SMTs) after treatment for childhood cancer (Meeting abstract). Increased risk of second malignant neoplasms (SMN) in young children with embryonal rhabdomyosarcoma (ERMS): Evidence for a cancer predisposition syndrome? Subsequent primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) in the modern treatment era. Males with Dysplastic Nevi (DN) Have a Higher than Expected History of Testis Cancer. Head and neck cancer in Fanconi anemia and dyskeratosis congenita.
		L1D522 (1.4)	T80 (20%): screening (7%), screening_program (4%), colposcopy (4%) T46 (9%): examination (4%), nodules (3%), chest_x-ray (2%), nodule (2%), exam (2%) T140 (7%): cervical_cancer (14%), cervical (8%) T0 (5%): fume (0%), center-ce (0%), leukocoria (0%), ceprec (0%), store-forward (0%) T54 (4%): hpv (20%) T3 (3%): world (6%), thailand (5%), mexico (4%), country (4%), usa (4%) T139 (3%): diagnostic (11%), specificity (8%), false_positive (7%), sensitivity (7%)	Prevalence of MGUS in a geriatric population in Turkey. Multifocal adenocarcinoma of the lung: Factors predictive for local therapy. Oncogenic HPV-DNA testing alone as cervical cancer screening in high-risk population of Southern Mexico. Cumulative false-positives (FP) in the prostate, lung, colorectal, ovarian (PLCO) cancer screening trial. Prevalence and outcomes of cancers in Ekiti State, southwest Nigeria.
		L1D568 (1.4)	T115 (10%): hiv (9%), kaposi_sarcoma (5%) T13 (7%): mecklenberg (0%), ptxm (0%), hiv-disease (0%), 15-24yrs (0%), sm** (0%) T99 (6%): lymphoma (7%), nhl (7%), lymphomas (7%), non-hodgkin_lymphoma (7%) T33 (4%): registries (7%), year-olds (4%) T3 (3%): century (6%), world (4%), italy (3%), international (3%), countries (3%) T72 (3%): national (10%), center (9%), united_states (9%), per_year (7%), hospital (5%) T15 (3%): age (34%) T195 (3%): children (12%), pediatric (10%), adult (7%), young_adults (7%) T341 (3%): registry (27%), diagnosed (26%) T273 (2%): population (37%) T306 (2%): males (25%), females (21%), male (18%), sex (17%) T109 (2%): mortality (8%), general_population (6%), both_sexes (6%), age-adjusted (6%) T325 (2%): increasing (21%), period (20%), over (17%)	Association of melanoma with glioblastoma multiforme. Clinical trial availability compared to incidence rates for adolescent and young adult cancer. Helicobacter pylori infection: An oncologist’s perspective Immune compromization and disparities in cancer type among sexual minority men. Early Signs of Improved Survival of Epithelial Ovarian Cancer During the 90¦s. Recent Results from the Population-Based Swedish Cancer Registry for Patients Diagnosed 1960-1998 (Inclusive).
L2D180 (1.3)	T3 (8%): countries (20%), country (16%), uk (15%), germany (14%), france (13%) T11 (8%): online (100%) T222 (6%): practice (26%), guidelines (22%), recommendations (21%), implementation (16%) T125 (5%): process (27%), implemented (19%), integrated (14%), list (13%) T127 (5%): oncologists (51%), physicians (42%) T40 (4%): fda (37%), scientific (29%), conduct (23%) T31 (3%): access (33%), research (20%) T180 (3%): pathologists (31%) T215 (3%): decision (15%), clinicians (14%), decisions (13%), make (12%), treatment_decisions (12%) T84 (3%): cost (60%) T260 (3%): use (29%), management (17%)	L1D547 (1.4)	T9 (8%): 97-october (1%), dowgradation (1%), genitale (1%), “expert” (1%), “strong (1%) T180 (7%): discordance (9%), pathologists (7%), kappa (5%), concordance (5%) T24 (7%): pathologist (5%), staining (4%), immunohistochemical_ihc (3%), cores (3%), stained (3%) T172 (6%): biopsies (19%), biopsy (15%), biopsied (10%) T60 (4%): er (10%), hormonal_receptors (6%), receptor_status (5%), estrogen_receptor (5%), er_pr (5%) T46 (2%): suspected (8%) T32 (2%): liver (32%), metastatic_sites (22%) T236 (2%): review (17%), reports (16%), search (11%), systematic (9%) T43 (2%): cases (34%) T235 (2%): malignant (13%), metastasis (11%), histological (10%), microscopic_examination (8%), omentum (7%) T276 (2%): tissue (26%), samples (25%) T160 (2%): her2 (19%) T260 (2%): management (15%), need (12%), inadequate (11%), often (9%), not_always (9%) T139 (2%): diagnostic (30%) T222 (1%): guidelines (6%), radiology_reports (5%), recommend (5%), expert (5%), certified (4%) T223 (1%): retrospective (17%), our_center (13%), prospective_studies (11%), we_retrospectively (10%), consecutive (9%)	Quality and cost comparison of powered versus manual bone marrow biopsy devices at a large U.S. cancer center. Factors influencing HER2 positivity in breast cancer according to statistical modeling and data mining techniques based on a real-world national database: HER-France. Quality of bone marrow biopsy as compared to the 2008 WHO guidelines. Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies. Optimal patient selection for electron intraoperative radiotherapy (IORT) as sole treatment for breast cancer.
		L1D719 (1.5)	T22 (7%): actionable (6%), ngs (4%) T130 (6%): alk (13%), molecular_testing (10%), targeted_therapies (10%), targeted_therapy (7%) T127 (5%): oncologists (8%), community (6%), medical_oncologists (5%), barriers (4%), physicians (4%) T222 (5%): practice (6%), tumor_board (6%), ordered (5%), implementation (5%), recommendations (4%) T132 (4%): egfr (23%) T40 (3%): industry (5%), approval (4%), launched (3%), conduct (3%), scientific (2%) T11 (3%): working (2%), ipsos (2%), sanford (2%), expanded_reflex (2%), inform_policy (1%) T31 (3%): access (12%), program (9%), availability (8%), research (7%) T13 (3%): compendia-based (1%), available-22 (1%), type-histology-driver (1%), €2m (1%), post-reflex (1%) T125 (3%): commercial (5%), virtual (4%), process (4%), list (3%), example (3%) T245 (2%): personalized_medicine (6%), panel (5%), platforms (5%), identification (4%), personalized (4%) T93 (2%): therapies (13%), off-label (9%), targeted_agents (8%), investigational (7%), across (7%) T78 (2%): survey (9%) T297 (2%): testing (51%)	Analysis of a United States observational registry of gastrointestinal stromal tumor (GIST) patients (pts): reGISTry. Evaluating causes of screen failure (SF) in non-small cell lung cancer (NSCLC) clinical trials requiring specific biomarker (BioM) results for enrollment. Personalized cancer therapy for patients with metastatic medullary thyroid cancer (MTC). Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK and ROS-1 versus next-generation sequence (NGS) in advanced adenocarcinoma lung cancer patients. Review of 200 consecutive patients with mutation profiling in a lung cancer individualized medicine clinic.
		L1D729 (1.6)	T11 (14%): experts (2%), training (1%), decision_support (1%), natural_language (1%), ibm_watson (1%) T125 (9%): created (5%), members (4%), create (3%), process (3%) T222 (7%): surgeons (4%), expert (4%), consensus (4%), surveillance_strategies (3%), electronic (3%) T13 (6%): ct-out-patient-clinics (0%), modellers (0%), esag (0%), decision-ready (0%), ‘central (0%) T215 (4%): clinicians (10%), treatment_decisions (6%), decisions (5%), decision (5%) T40 (4%): requirements (4%), investigators (4%), formal (4%), reviewers (3%), collaboration (3%) T180 (3%): tool (10%) T78 (3%): mailed (4%), respondents (4%), repeated-measures_anova (3%), asked (3%), survey (3%) T127 (3%): office_visit (6%), physicians (5%), oncologists (5%), physician (3%), service (3%)	Effect of Initial Tumor Stage on Patient Follow-up After Potentially Curative Surgery for Cutaneous Melanoma. Evaluation of patients with clinically detected recurrence of rectal carcinoma: Current practice patterns of colorectal surgeons. International application of an online clinical informatics expert system for breast cancer. Global impact of a clinical informatics system: Scalable delivery of on-time access to evidence-based multidisciplinary expert treatment decisions for all cancers. An app to increase cross-referral and recruitment to melanoma clinical trials.
		L1D786 (1.7)	T3 (38%): countries (6%), uk (4%), france_germany (3%), france (3%) T84 (8%): cost (5%), prices (4%), capita (4%), costs (3%) T93 (4%): approved (11%), therapies (10%), market (10%), across (9%), new_drugs (9%) T127 (3%): physicians (7%), health_care (6%), reimbursement (5%), spending (4%), spent (4%)	Influence of market access conditions on utilization of innovative drugs in Europe: The cases of trastuzumab and cetuximab. Trends in biomarker testing among metastatic colorectal cancer patients: A temporal description of KRAS , NRAS, and BRAF testing in the EU5. Proportional shortfall due to pancreatic cancer in Europe: Survival and quality of life analysis based on a systematic review. Survey on management of metastatic hormone-refractory prostate cancer upon progression during or following first-line chemotherapy in five European countries. Geographical distribution of industry driven clinical trials performed for leukemia over the last ten years.